Sanofi: Dupixent approved in China
(CercleFinance.com) - Sanofi has announced that Dupixent (dupilumab) has been approved the National Medical Products Administration (NMPA) of China for the treatment of moderate-to-severe atopic dermatitis in adults.
The NMPA has identified Dupixent as a foreign drug that is urgently needed in clinical practices in China, thereby accelerating its evaluation and approval process.
Atopic dermatitis is a chronic inflammatory disease that is most commonly seen as a rash.
Dupixent has been approved in 60 countries for the treatment of moderate-to-severe atopic dermatitis in adults - one of the diseases mediated by type 2 inflammation.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The NMPA has identified Dupixent as a foreign drug that is urgently needed in clinical practices in China, thereby accelerating its evaluation and approval process.
Atopic dermatitis is a chronic inflammatory disease that is most commonly seen as a rash.
Dupixent has been approved in 60 countries for the treatment of moderate-to-severe atopic dermatitis in adults - one of the diseases mediated by type 2 inflammation.
Copyright (c) 2020 CercleFinance.com. All rights reserved.